Instrument Inactif

Communiqués ProMIS Neurosciences, Inc. Toronto S.E.

Actions

PMN

CA74346M4065

Recherche biotechnologique et médicale

Communiqués

01/09	ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September	AQ
13/08	ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights	AQ
03/08	ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026	AQ
28/07	ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial	AQ
27/07	ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease	AQ
14/07	ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026	AQ
28/05	ProMIS Neurosciences to Participate in Upcoming Conferences in June	AQ
12/05	ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights	AQ
27/04	ProMIS Neurosciences : Targeting underlying causes of neurodegenerative diseases \| 2026 Bloom Burton & Co. Healthcare Investor Conference	PU
13/04	ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference	NE
25/03	ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights	AQ
18/03	ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)	AQ
04/02	ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026	AQ
30/01	ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing	AQ
18/12	ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease	AQ
10/12	ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk	AQ
01/12	ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310	AQ
01/12	ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference	AQ
24/11	ProMIS Neurosciences Announces Reverse Stock Split	GL
24/11	ProMIS Neurosciences Announces Reverse Stock Split	AQ
12/11	ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights	GL
12/11	ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights	AQ
03/11	ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference	GL
22/10/25	ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group	GL
18/09/25	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics	AQ